Oncocyte Corp Files 8-K: Material Agreement, Equity Sales

Ticker: IMDX · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1642380

Sentiment: neutral

Topics: material-agreement, equity-sale, regulation-fd

TL;DR

Oncocyte signed a big deal, sold some stock, and dropped an 8-K. Watch this space.

AI Summary

On October 2, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits, with the report being filed as of October 3, 2024.

Why It Matters

This 8-K filing indicates significant corporate activity for Oncocyte, including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity securities and a material definitive agreement, which can introduce financial and operational risks if not managed properly.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by Oncocyte Corporation?

The filing states that Oncocyte Corporation entered into a Material Definitive Agreement on October 2, 2024, but the specific terms and details of this agreement are not disclosed in this particular 8-K filing.

What type of unregistered sales of equity securities are reported?

The filing indicates unregistered sales of equity securities occurred, but the specific details regarding the type of securities, the number of shares, or the price are not provided in this document.

What is the purpose of the Regulation FD Disclosure mentioned in the filing?

The Regulation FD Disclosure item suggests that Oncocyte Corporation is providing information to ensure fair disclosure of material non-public information to all investors, as required by the SEC.

When was the report filed with the SEC, and what is the earliest event date reported?

The report was filed as of October 3, 2024, and the earliest event reported is dated October 2, 2024.

What are the company's primary business activities based on its SIC code?

Oncocyte Corporation's Standard Industrial Classification (SIC) code is 2835, which pertains to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.

Filing Stats: 1,480 words · 6 min read · ~5 pages · Grade level 12.9 · Accepted 2024-10-03 06:05:29

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: October 3, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing